Hutchmed的癌症药物FRUZAQLA(fruquinitinib)由Takeda制药公司在日本批准。 Hutchmed's cancer drug FRUZAQLA® (fruquintinib) approved in Japan by Takeda Pharmaceutical.

HUCHMED宣布其癌症药物FRUZAQLA(fruquinitinib)已在日本获得批准,Takeda制药公司获得批准。 HUTCHMED announced that its cancer drug FRUZAQLA® (fruquintinib) has been approved in Japan, with Takeda Pharmaceutical as the recipient of the approval. 这标志着日本在为癌症病人提供治疗方案方面取得了重大进展。 This marks a significant advancement in the treatment options available for cancer patients in Japan.